Výsledky vyhledávání - "L A A P Derikx"

P789 Inflammatory Bowel Disease subgroups identified by longitudinal faecal calprotectin profiles: A 10-year retrospective analysis of the Lothian IBD Registry

Autor: N Constantine-Cooke, K Monterrubio-Gómez, N Plevris, L A A P Derikx, M Lyons, P W Jenkinson, B Gros, G R Jones, C A Vallejos, C W Lees

Publikováno v: Journal of Crohn's and Colitis. 17:i921-i924

Background Faecal calprotectin (FCAL) is routinely used to monitor mucosal inflammation, and high FCAL values are associated with poor outcomes in IBD. Having previously found clusters characterised by distinct FCAL profiles in a Crohn’s disease (C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b6a9465266177de8d9108af839a64b8
https://doi.org/10.1093/ecco-jcc/jjac190.0919

Zobrazit plný text záznamu

P725 Patients with Immune Mediated Inflammatory Diseases are insufficiently protected against vaccine-preventable influenza and pneumococcal infections due to low vaccination rates

Autor: N Van De Pol, C J van der Woude, M Vis, M B A van Doorn, L A A P Derikx, I Molendijk, A C de Vries

Publikováno v: Journal of Crohn's and Colitis. 17:i856-i857

Background Patients with Immune Mediated Inflammatory Diseases (IMIDs) treated with immunosuppressive drugs are at an increased risk of infections and a more complicated course of the infection, including vaccine-preventable infections. National and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ef5856df73c072fbede82b97e171db7a
https://doi.org/10.1093/ecco-jcc/jjac190.0855

Zobrazit plný text záznamu

P827 SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with Inflammatory Bowel Disease: A systematic review and meta-analysis

Autor: N Van De Pol, Q Pan, L A A P Derikx, L Bakker, C J van der Woude, A C de Vries

Publikováno v: Journal of Crohn's and Colitis. 17:i960-i961

Background Patients with inflammatory bowel disease (IBD) have reduced seroconversion rates to COVID-19 vaccination. It is unclear whether an impaired immune response in vaccinated IBD patients impacts the susceptibility to SARS-CoV-2 infection and o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::674d12e7d26177225f7db798a58c991c
https://doi.org/10.1093/ecco-jcc/jjac190.0957

Zobrazit plný text záznamu

P745 Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort

Autor: B Gros, N Plevris, N Constantine-Cooke, M Lyons, C O’Hare, C Noble, I D Arnott, G R Jones, C W Lees, L A A P Derikx

Publikováno v: Journal of Crohn's and Colitis. 17:i876-i876

Background Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ecbbd426126abe3cdaa52f24bad0c781
https://doi.org/10.1093/ecco-jcc/jjac190.0875

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání